2025
95 Assessing genetic diversity of the Pfs25 vaccine candidate: Implications for malaria transmission-blocking vaccine in Africa
Orfano A, Cisse A, Sheng Z, Guo Y, Han L, Thiam L, Mangou K, Moore A, Ba A, Li R, Pouye M, Diallo F, Sene S, Ngom E, Sadio B, Mbengue A, Membi C, Bazié T, Somé F, Olson N, Patel S, Shapiro L, Parikh S, Foy B, Cappello M, Premji Z, Dabiré R, Ouedraogo J, Bei A. 95 Assessing genetic diversity of the Pfs25 vaccine candidate: Implications for malaria transmission-blocking vaccine in Africa. Journal Of Clinical And Translational Science 2025, 9: 29-29. PMCID: PMC12050472, DOI: 10.1017/cts.2024.767.Peer-Reviewed Original ResearchSingle nucleotide polymorphismsTransmission-blocking vaccinesGenetic diversityComplex infectionSymptomatic P. falciparum infectionsMalaria transmission-blocking vaccineVaccine candidatesVariant frequenciesNovel single nucleotide polymorphismsNonsynonymous single nucleotide polymorphismsRare variantsFrequency of single nucleotide polymorphismsP. falciparum 3D7Plasmodium falciparum samplesAmplicon deep sequencingMalaria eliminationCountry-specific prevalenceEndemic African countriesPfs25 proteinGeneious softwareParasite genetic diversityProportion of mutant allelesAmplicon sequencingPfs25Mutant allelesmosGILT antibodies interfere with Plasmodium sporogony in Anopheles gambiae
Dolan B, Correa Gaviria T, Dong Y, Cresswell P, Dimopoulos G, Chuang Y, Fikrig E. mosGILT antibodies interfere with Plasmodium sporogony in Anopheles gambiae. Nature Communications 2025, 16: 592. PMID: 39799117, PMCID: PMC11724845, DOI: 10.1038/s41467-025-55902-1.Peer-Reviewed Original ResearchConceptsCausative agent of malariaTransmission-blocking vaccinesMurine infection modelPlasmodium life cycleAgent of malariaGamma-interferon-inducible lysosomal thiol reductaseP. falciparumInfection modelAnopheles gambiaeMosquito midgutPlasmodiumLysosomal thiol reductaseCausative agentAntibodiesOocyst stageInfection prevalenceThiol reductaseMalariaGambiaInfectionMosquitoesPrevalenceVaccineDistinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1
Cao Y, da Silva Araujo M, Lorang C, Dos Santos N, Tripathi A, Vinetz J, Kumar N. Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1. Vaccine 2025, 47: 126696. PMID: 39787798, PMCID: PMC11781949, DOI: 10.1016/j.vaccine.2024.126696.Peer-Reviewed Original ResearchConceptsTransmission-reducing activityTransmission-blocking vaccinesDirect membrane feeding assaysStandard membrane feeding assayTransmission-blocking vaccine candidateMembrane feeding assaysDNA vaccineP. vivaxSexual-stage antigensSurface of gametocytesEfficacy of DNA vaccinesPreclinical immunogenicity studiesVaccine target antigensComplement-dependent mannerIn vivo electroporationInhibit parasite developmentImmunogenicity outcomesLow antibody avidityMalaria controlP. falciparumPreclinical studiesPlasmodium falciparumClinical trialsImmunogenicity studiesTarget antigen
2024
Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45
Bansal G, da Silva Araujo M, Cao Y, Shaffer E, Araujo J, Medeiros J, Hayashi C, Vinetz J, Kumar N. Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45. Infection And Immunity 2024, 92: e00374-23. PMID: 38289124, PMCID: PMC10929423, DOI: 10.1128/iai.00374-23.Peer-Reviewed Original ResearchDirect membrane feeding assaysTransmission-blocking vaccinesTransmission-blocking vaccine developmentMalaria transmission-blocking vaccineBlocked oocyst developmentInfectivity of gametocytesMale gamete fertilityMonoclonal antibodiesMembrane feeding assaysTransmission-blocking activityPvs48/45Activity of antibodiesNon-overlapping epitopesOocyst developmentPotential vaccine candidatesIndividual MAbsVaccine candidatesEffective immunogensChallenge modelMAbAntibodiesGametocytesEpitopesRecombinant fragmentsEnhanced activity
2022
Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
Mulamba C, Williams C, Kreppel K, Ouedraogo J, Olotu A. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria Journal 2022, 21: 159. PMID: 35655174, PMCID: PMC9161629, DOI: 10.1186/s12936-022-04173-y.Peer-Reviewed Original ResearchConceptsEndemic settingsMalaria transmission-blocking vaccineHuman vaccine trialsTransmission-blocking vaccinesPublic health importanceMosquito vectorsMiddle-income settingsAnti-malarial drugsImmunological mechanismsCandidate vaccinesVaccine trialsHealthy individualsIncome settingsTransmission blockingHealth importanceMalaria controlMalaria parasitesVaccineLocal interventionsDrugsInterventionSettingSexual stagesPfs25Disease
2021
Transmission-Blocking Preventive Measures for Infectious Diseases: Altruism, Solidarity, and the Common Good
Garber L, Vinetz JM. Transmission-Blocking Preventive Measures for Infectious Diseases: Altruism, Solidarity, and the Common Good. American Journal Of Tropical Medicine And Hygiene 2021, 104: 1609-1610. PMID: 33705347, PMCID: PMC8103472, DOI: 10.4269/ajtmh.20-1005.Peer-Reviewed Original Research
2018
Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study
White SE, Harvey SA, Meza G, Llanos A, Guzman M, Gamboa D, Vinetz JM. Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study. Malaria Journal 2018, 17: 179. PMID: 29703192, PMCID: PMC5921293, DOI: 10.1186/s12936-018-2328-z.Peer-Reviewed Original ResearchConceptsTransmission-blocking malaria vaccineTransmission-blocking vaccinesMalaria vaccineMalaria transmission-blocking vaccineMalaria hypoendemic regionMalaria vaccine strategyProspective cohort studyMalaria-endemic communitiesMalaria-endemic regionsPre-validated questionnaireCohort studyVaccine strategiesMalaria infectionMethodsThe studyVaccineMalaria controlMalaria researchMultiple injectionsOne-thirdIndustrialized worldInjectionAcceptabilityCohortInfectionStudyAsymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination
Martin TCS, Vinetz JM. Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination. Malaria Journal 2018, 17: 89. PMID: 29466991, PMCID: PMC5822557, DOI: 10.1186/s12936-018-2243-3.Peer-Reviewed Original ResearchConceptsTransmission-blocking vaccinesPlasmodium vivax parasitaemiaLow transmission settingsControl of transmissionVivax parasitaemiaChloroquine resistanceAsymptomatic carriageMalaria eliminationNew therapiesPlasmodium vivaxImportant causeCarrier stateImmunological interactionsVaccineOnward infectionInfectionParasite transmissionEradication effortsMosquitoesMorbidityParasitaemiaTherapyMortalityDiagnosisVivax
2013
Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds
Da D, Dixit S, Sattabonkot J, Mu J, Abate L, Ramineni B, Ouedraogo J, MacDonald N, Fay M, Su X, Cohuet A, Wu Y. Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds. Infection And Immunity 2013, 81: 1984-1989. PMID: 23509152, PMCID: PMC3676035, DOI: 10.1128/iai.00016-13.Peer-Reviewed Original ResearchConceptsPhase 1 trialParasite isolatesMalaria transmission-blocking vaccineTransmission-reducing activityTransmission-blocking activityPlasmodium falciparum isolatesTransmission-blocking vaccinesPlasmodium falciparum parasitesLimited sequence polymorphismPfs25 antibodiesMontanide ISA51Immune plasmaNonimmune controlsRecombinant Pfs25Falciparum isolatesPfs25 geneFalciparum parasitesGenetic backgroundPatientsBurkina FasoPfs25VaccineTrialsNucleotide polymorphismsIsolates
2009
Chlamydia trachomatis Native Major Outer Membrane Protein Induces Partial Protection in Nonhuman Primates: Implication for a Trachoma Transmission-Blocking Vaccine
Kari L, Whitmire W, Crane D, Reveneau N, Carlson J, Goheen M, Peterson E, Pal S, de la Maza L, Caldwell H. Chlamydia trachomatis Native Major Outer Membrane Protein Induces Partial Protection in Nonhuman Primates: Implication for a Trachoma Transmission-Blocking Vaccine. The Journal Of Immunology 2009, 182: 8063-8070. PMID: 19494332, PMCID: PMC2692073, DOI: 10.4049/jimmunol.0804375.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, BacterialAntibody SpecificityBacterial Outer Membrane ProteinsBacterial VaccinesChlamydia InfectionsChlamydia trachomatisCytokinesDisease Models, AnimalEnzyme-Linked Immunosorbent AssayHeLa CellsHumansKineticsLeukocytesMacaca fascicularisMaleProtein DenaturationTitrimetryConceptsMuridarum major outer membrane proteinChlamydia muridarum major outer membrane proteinInfectious burdenAg-specific IFN-gamma responseBlinding inflammatory diseaseReduces infectious burdenProgression of ocular diseaseNonhuman primatesInfection of childrenTransmission-blocking vaccinesIFN-gamma responseHuman chlamydial infectionsHigher serum IgGDuration of infectionMajor Outer Membrane ProteinOcular sheddingOcular diseasesChlamydial infectionImmunized monkeysAb titersCynomolgus monkeysNeutralizing activityPrimary infectionChlamydial challengeInflammatory diseases
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply